- Home
- TLRY vs ABUS Comparison
TLRY vs ABUS Comparison
Compare TLRY & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLRY
- ABUS
- Stock Information
- Founded
- TLRY N/A
- ABUS 2005
- Country
- TLRY Canada
- ABUS United States
- Employees
- TLRY N/A
- ABUS N/A
- Industry
- TLRY Medicinal Chemicals and Botanical Products
- ABUS Biotechnology: Pharmaceutical Preparations
- Sector
- TLRY Health Care
- ABUS Health Care
- Exchange
- TLRY Nasdaq
- ABUS Nasdaq
- Market Cap
- TLRY 624.7M
- ABUS 611.0M
- IPO Year
- TLRY 2018
- ABUS N/A
- Fundamental
- Price
- TLRY $1.13
- ABUS $3.60
- Analyst Decision
- TLRY Hold
- ABUS Strong Buy
- Analyst Count
- TLRY 3
- ABUS 3
- Target Price
- TLRY $1.38
- ABUS $5.67
- AVG Volume (30 Days)
- TLRY 75.7M
- ABUS 689.0K
- Earning Date
- TLRY 10-09-2025
- ABUS 08-06-2025
- Dividend Yield
- TLRY N/A
- ABUS N/A
- EPS Growth
- TLRY N/A
- ABUS N/A
- EPS
- TLRY N/A
- ABUS N/A
- Revenue
- TLRY $821,309,000.00
- ABUS $15,416,000.00
- Revenue This Year
- TLRY $8.95
- ABUS $3.35
- Revenue Next Year
- TLRY $4.76
- ABUS N/A
- P/E Ratio
- TLRY N/A
- ABUS N/A
- Revenue Growth
- TLRY 4.10
- ABUS 53.23
- 52 Week Low
- TLRY $0.35
- ABUS $2.71
- 52 Week High
- TLRY $1.95
- ABUS $4.73
- Technical
- Relative Strength Index (RSI)
- TLRY 66.28
- ABUS 68.78
- Support Level
- TLRY $1.01
- ABUS $3.44
- Resistance Level
- TLRY $1.37
- ABUS $3.45
- Average True Range (ATR)
- TLRY 0.13
- ABUS 0.12
- MACD
- TLRY 0.02
- ABUS 0.02
- Stochastic Oscillator
- TLRY 70.14
- ABUS 93.00
About TLRY Tilray Brands Inc.
Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. USA exposure consists of CBD products and alcohol.
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.